HUM Share Price | Humana, Inc. Stock Analysis & Recommendation

Q: How big is Humana, Inc.?

Market Cap: As of Jun 18, Humana, Inc. has a market capitalization of 46,070.57 million, categorizing it as a Large Cap company.Recent Quarterly Performance: For the latest four quarters, Humana, Inc. reported net sales of 0.00 million and a net profit of 1,717.00 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 16,375.00 million and total assets of 46,312.00 million.

Q: What does Humana, Inc. do?

Overview: Humana, Inc. is a health and well-being company operating in the Healthcare Services industry, with a market capitalization in the large-cap bracket.Financial Snapshot: Net Profit: 1,242 Million (Quarterly Results - Mar 2025) Market Cap: USD 46,070.57 Million (Large Cap)Key Metrics: P/E: 26.00 Dividend Yield: 3.78% Debt Equity: -0.50 Return on Equity: 9.67% Price to Book: 2.60Contact Details: Address: 500 W Main St, LOUISVILLE KY: 40202 Tel: ['1 502 5801000', '1 502 5802811'] Fax: 1 302 6365454 Website: http://www.humana.com/

Q: Who are in the management team of Humana, Inc.?

As of March 2022, the management team of Humana, Inc. includes the following individuals:- Mr. Kurt Hilzinger, who serves as the Independent Chairman of the Board.- Mr. Bruce Broussard, who is the President, Chief Executive Officer, and a Director.- Mr. Frank Bisignano, serving as an Independent Director.- Dr. Raquel Bono, also an Independent Director.- Mr. Frank D'Amelio, another Independent Director.- Dr. Wayne Frederick, who is an Independent Director as well.- Mr. John Garratt, serving as an Independent Director.In summary, as of March 2022, Humana, Inc.'s management team consists of a mix of independent directors and key executives, including the CEO and Chairman of the Board.

Q: Is Humana, Inc. overvalued or undervalued?

As of 30 June 2025, Humana, Inc. has moved from expensive to very expensive, indicating a significant shift in its valuation outlook. The company is considered overvalued, with a P/E ratio of 26, which is substantially higher than its peer Centene Corp., which has a P/E of 6.94. Additionally, Humana's EV to EBITDA stands at 37.39, again reflecting a premium compared to Centene's 11.91, further supporting the overvaluation assessment. The price to book value is 2.48, suggesting that investors are paying a high price relative to the company's net assets.In terms of recent performance, Humana has underperformed compared to the S&P 500, with a 1-year return of -15.99% versus the S&P 500's 17.14%, and a staggering 3-year return of -47.01% compared to the S&P 500's 70.41%. This trend reinforces the notion that the stock is overvalued in the current market context.

Q: Is Humana, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Humana, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages indicate a mildly bullish stance. However, the weekly KST is mildly bearish, and the Bollinger Bands show a mildly bearish signal on the monthly timeframe. The Dow Theory reflects a mildly bullish trend on the weekly basis but shows no trend monthly.In terms of performance, Humana has underperformed the S&P 500 across multiple periods, with a year-to-date return of 11.10% compared to the S&P 500's 16.30%, and a one-year return of 8.12% against the S&P 500's 19.89%. Overall, the current technical stance is mildly bullish, but the strength is tempered by mixed signals from various indicators.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

2.1 M

Shareholding (Sep 2025)

FII

19.22%

Held by 479 FIIs

DII

20.67%

Held by 76 DIIs

Promoter

0.10%

How big is Humana, Inc.?

22-Jun-2025

As of Jun 18, Humana, Inc. has a market capitalization of $46.07 billion, with recent net sales of $0 million and a net profit of $1.72 billion. The company reported shareholder's funds of $16.38 billion and total assets of $46.31 billion as of Dec 24.

View full answer

What does Humana, Inc. do?

22-Jun-2025

Humana, Inc. is a large-cap health and well-being company in the Healthcare Services industry, with a market cap of approximately $46.07 billion and a quarterly net profit of $1.24 billion. Key metrics include a P/E ratio of 26.00, a dividend yield of 3.78%, and a return on equity of 9.67%.

View full answer

Who are in the management team of Humana, Inc.?

22-Jun-2025

As of March 2022, Humana, Inc.'s management team includes Independent Chairman Kurt Hilzinger, CEO Bruce Broussard, and several Independent Directors: Frank Bisignano, Raquel Bono, Frank D'Amelio, Wayne Frederick, and John Garratt.

View full answer

Is Humana, Inc. overvalued or undervalued?

20-Sep-2025

As of June 30, 2025, Humana, Inc. is considered overvalued with a P/E ratio of 26 compared to Centene Corp.'s 6.94, an EV to EBITDA of 37.39 versus Centene's 11.91, and has underperformed the S&P 500 with a 1-year return of -15.99% and a 3-year return of -47.01%.

View full answer

Is Humana, Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Humana, Inc. shows a mildly bullish technical trend, supported by bullish weekly MACD and daily moving averages, but tempered by mixed signals from the weekly KST and monthly Bollinger Bands, while underperforming the S&P 500 year-to-date and over the past year.

View full answer

Compare Humana, Inc. with Similar Stocks

The Cigna Group Elevance Health, Inc.UnitedHealth Group, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 17.30%

The company declared positive results in Mar'25 after very negative results in Dec'24

With ROE of 9.67%, it has a very expensive valuation with a 2.48 Price to Book Value

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Industry

Healthcare Services

Market cap

USD 32,554 Million (Mid Cap)

P/E

26.00

Industry P/E

Dividend Yield

1.25%

Debt Equity

-0.51

Return on Equity

7.00%

Price to Book

1.76

Revenue and Profits:

Net Sales:

(Quarterly Results - Jun 2025)

Net Profit:

543 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

-23.55%

6 Months

-32.8%

1 Year

-45.02%

2 Years

-62.58%

3 Years

-56.76%

4 Years

-54.37%

5 Years

-51.07%

Humana, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

11.77%

EBIT Growth (5y)

EBIT to Interest (avg)

0.11

Debt to EBITDA (avg)

14.09

Net Debt to Equity (avg)

0.75

Sales to Capital Employed (avg)

3.82

Tax Ratio

23.69%

Dividend Payout Ratio

35.45%

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

17.30%

Valuation key factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.48

EV to EBIT

EV to EBITDA

37.39

EV to Capital Employed

3.95

EV to Sales

0.29

PEG Ratio

Dividend Yield

3.95%

ROCE (Latest)

ROE (Latest)

9.67%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bearish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 186 Schemes (59.99%)

Foreign Institutions

Held by 479 Foreign Institutions (19.22%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -56.28% vs 281.84% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "211.00",
          "val2": "215.00",
          "chgp": "-1.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "157.00",
          "val2": "160.00",
          "chgp": "-1.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "543.00",
          "val2": "1,242.00",
          "chgp": "-56.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "33.90%",
          "val2": "62.70%",
          "chgp": "-2.88%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -51.13% vs -11.35% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "968.00",
          "val2": "917.00",
          "chgp": "5.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "660.00",
          "val2": "493.00",
          "chgp": "33.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-200.00",
          "val2": "-125.00",
          "chgp": "-60.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,214.00",
          "val2": "2,484.00",
          "chgp": "-51.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "23.40%",
          "val2": "38.90%",
          "chgp": "-1.55%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

211.00

215.00

-1.86%

Interest

157.00

160.00

-1.88%

Exceptional Items

0.00

Consolidate Net Profit

543.00

1,242.00

-56.28%

Operating Profit Margin (Excl OI)

33.90%

62.70%

-2.88%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -56.28% vs 281.84% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

968.00

917.00

5.56%

Interest

660.00

493.00

33.87%

Exceptional Items

-200.00

-125.00

-60.00%

Consolidate Net Profit

1,214.00

2,484.00

-51.13%

Operating Profit Margin (Excl OI)

23.40%

38.90%

-1.55%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -51.13% vs -11.35% in Dec 2023

All Annual Results

Company CV

About Humana, Inc.

Humana, Inc.

Healthcare Services

Humana Inc. is a health and well-being company. The Company's segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, including dental, vision, and other supplemental health and financial protection products. The Healthcare Services segment includes services offered to its health plan members, as well as to third parties, including pharmacy solutions, provider services, home-based services and clinical programs, as well as services and capabilities to manage population health. The Individual Commercial segment includes Individual Commercial products marketed under the HumanaOne brand.

Company Coordinates

Company Details

500 W Main St , LOUISVILLE KY : 40202

Tel: 1 502 58010001 502 5802811

http://www.humana.com/

Registrar Details

Humana, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Humana, Inc.?

Watch in Real-Time

What does Humana, Inc. do?

Who are in the management team of Humana, Inc.?

Is Humana, Inc. overvalued or undervalued?

Is Humana, Inc. technically bullish or bearish?

Compare Humana, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 17.30%

The company declared positive results in Mar'25 after very negative results in Dec'24

With ROE of 9.67%, it has a very expensive valuation with a 2.48 Price to Book Value

Consistent Underperformance against the benchmark over the last 3 years

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Humana, Inc.

Company Coordinates